PARNAX LAB LTD.

Parnax Lab Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from July 1, 2026, and will remain in effect until 48 hours after the unaudited financial results for the quarter and three months ended June 30, 2026, are made public. The measure is in compliance with BSE circulars and is intended to prevent insider trading during the period leading up to the financial results announcement.

Mihir Prakash Shah, a promoter of Parnax Lab Ltd, has intimated the stock exchange about his proposed acquisition of 3,77,355 equity shares, representing 3.29% of the company's total share capital. The acquisition will be through an inter-se transfer by way of a gift from Baiju Mahasukhlal Shah, another promoter. This transaction falls under an exemption from open offer requirements as per SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Post-acquisition, the shareholding of the Promoter and Promoter Group will remain unchanged in aggregate. The acquisition is planned to occur after 4 working days from the date of the intimation.

Prakash Mahasukhlal Shah, a promoter of Parnax Lab Limited, has disclosed his intention to acquire 3,61,872 equity shares, representing 3.15% of the total share capital, from Ila B. Shah, another promoter. The acquisition will be conducted through an inter-se transfer by way of gift, falling under an exemption from open offer requirements as per SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Post-transaction, the shareholding of the Promoter and Promoter Group will remain unchanged in aggregate, though individual holdings will shift. The transaction is expected to occur any time after 4 working days from the date of intimation.

Parnax Lab Limited's Board of Directors approved the standalone and consolidated audited financial results for the quarter and year ended March 31, 2026. Concurrently, the Board, based on the Nomination & Remuneration Committee's recommendation, approved the re-appointment of Mr. Yogesh K. Varia as a Non-Executive Independent Director for a second term of five consecutive years, effective from May 28, 2026, to May 27, 2031. This re-appointment is subject to approval by members at the upcoming General Meeting. The company confirmed that Mr. Varia is not debarred from holding a directorship by any regulatory authority. The auditors expressed an unmodified opinion on the standalone audited financial results.

Parnax Lab Limited's Board of Directors, at its meeting on May 28, 2026, approved the Standalone and Consolidated Audited Financial Results for the quarter and year ended March 31, 2026. The company also confirmed that the auditors have expressed an unmodified opinion on the Standalone Audited Financial Results. Additionally, the Board approved the re-appointment of Mr. Yogesh K. Varia as a Non-Executive Independent Director for a second term of five consecutive years, effective from May 28, 2026, to May 27, 2031, subject to approval by members at the upcoming General Meeting.

Parnax Lab Limited's Board of Directors convened on May 28, 2026, to approve the Standalone & Consolidated Audited Financial Results for the quarter and year ended March 31, 2026. The Board also confirmed that the auditors expressed an unmodified opinion on the standalone financial results. Additionally, Mr. Yogesh K. Varia was re-appointed as a Non-Executive Independent Director for a second term of five consecutive years, effective from May 28, 2026, to May 27, 2031. This re-appointment is contingent upon approval from the company's members at the upcoming General Meeting. Mr. Varia brings over 40 years of experience in pharmaceutical and cosmetics manufacturing.

Parnax Lab Ltd has scheduled a Board of Directors meeting on May 28, 2026, to consider and approve the Standalone and Consolidated Audited IND-AS Compliant Financial Results along with the Auditor's Report for the quarter (Q4) and year ended March 31, 2026. The trading window has been closed from April 1, 2026, and will open 48 hours after the declaration of the audited financial results.

Parnax Lab Ltd has announced the closure of the trading window for all insiders, designated persons, and their immediate relatives, effective from 01st April 2026. The closure is in preparation for the consideration of the Audited Financial Result for the Quarter and Year ended 31st March, 2026. The trading window will reopen 48 hours after the audited financial results become publicly available.

Parnax Lab Ltd has announced its financial results for the quarter and nine months ended December 31, 2025. The company's standalone and consolidated unaudited financial results were approved at a Board of Directors meeting. The results show a profit before exceptional items and tax of INR 19,483 Lakhs for the nine months ended December 31, 2025, and a total comprehensive income of INR 14,782 Lakhs for the same period.

Parnax Lab Ltd. has announced its financial results for the quarter and nine months ended December 31, 2025. The company's profit before tax stands at ₹ 19,267 Lakhs, and the total comprehensive income for the period is ₹ 14,782 Lakhs. The results were reviewed by the Audit Committee and approved by the Board of Directors on February 13, 2026. The company has also assessed and disclosed the incremental impact of the new Labour Codes on its financial results.